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Summary
Studies on the mechanism of action of the antitumor
agent azinomycin B in vitro suggest that the drug
elicits its lethal effects by the formation of interstrand
crosslinks within the major groove of DNA. Here, we
demonstrate the biological effects of the drug in vivo.
Fluorescence imaging revealed localization of azino-
mycin B in the nuclear region of yeast. Moreover, ex-
periments with oligonucleotide microarrays examined
the effects of the drug across the yeast transcriptome.
The results demonstrated a robust DNA damage re-
sponse that supports the proposed role of the drug
as a covalent DNA modifying agent. RT-PCR analysis
validated the gene changes, and flow cytometry of
azinomycin-treated yeast cells demonstrated a pheno-
typic S phase shift consistent with transcriptional
effects.
Introduction
Azinomycins A and B (Figure 1) are naturally occurring
antitumor agents that are among a small set of mole-
cules that interact with DNA in the major groove (for a
review of agents that covalently modify DNA, see [1]).
Azinomycin B was originally isolated fromStreptomyces
sahachiroi in 1954 as carzinophilin A [2] and, along with
azinomycin A, was subsequently reisolated from another
Streptomyces strain, S. griseofuscus, in 1986 [3, 4]. The
total synthesis of azinomycin A was achieved in 2001 [5],
and numerous reports on synthetic approaches to these
natural products have been reported [6, 7].
The seminal discovery that azinomycin B interacts
with DNA, forming interstrand crosslinks without prior
activation, was achieved by Lown and Majumdar [8].
Since this initial demonstration, a substantial number
of in vitro studies have revealed both the regioselectivity
and apparent sequence selectivity of the compound
[9–13]. Azinomycin B interacts with the duplex DNA se-
quence 50-d(PuNPy)-30 [9, 11] to form covalent inter-
strand crosslinks via the electrophilic C10 and C21 car-
bons of azinomycin and the N7 positions of suitably
disposed purine bases [9, 13]. Kinetic assays together
*Correspondence: watanabe@mail.chem.tamu.edu
4 These authors contributed equally to the experimental portion of
this work.with synthetic work further suggest that the monoalky-
lated product is formed first through reaction with the
aziridine, followed by crosslinking with the epoxide [9].
The highest levels of crosslinked product are attained
with the DNArecognitionsequence50-d(GGC$CCG)-30 [9].
Viscometry, fluorescence contact energy transfer, and
DNA unwinding experiments to probe the role of the
azinomycin naphthoate point to a nonintercalative bind-
ing mode for this group [9]. This is in contrast to the
neocarzinostatin naphthoate, which, despite structural
similarity with the azinomycin naphthoate, has been
demonstrated to exhibit an intercalative binding mode
[14]. In support of these results, computer modeling
studies point to a nonintercalative binding mode for
this molecule [15, 16]. These results, however, still leave
unanswered the question of whether DNA is the relevant
cellular target of this agent.
Despite extensive work to characterize the interaction
of azinomycin B with its DNA receptor in vitro, data on
the in vivo actions of the molecule are limited to the initial
description of its cytotoxicity and an early phase clinical
investigation [17, 18]. In this report, the natural products
were shown to exhibit potent cytotoxic activity (IC50 =
0.07 mg/ml [Figure 1A] and 0.11 mg/ml [Figure 1B])
against the leukemia cell line L5178Y. Azinomycin B
(Figure 1B) provided a 193% increased life span (ILS)
at 32 mg/kg/day (3/7 survivors) against an IP-implanted
P388 leukemia mouse model. In the same system, mito-
mycin C exhibited a 204% ILS, but at 1 mg/kg/day. A
preliminary clinical investigation with the compound
(Figure 1B) gave favorable results in 36 cases of malig-
nant neoplasms. Remarkable efficacy was observed
in a case of squamous cell carcinoma (a form of skin
cancer). Local administration of the agent led to rapid re-
duction of the ulcer surface and eventual disappearance
of the tumor cells [18].
Herein, we provide the first evidence for in vivo DNA
damage by azinomycin B by using cellular localization
studies and transcriptional profiling experiments across
the yeast genome. Our results suggest that the well-
established DNA alkylation and crosslinking exhibited
by this agent in vitro are likely biologically relevant to
lesions in vivo.
Results and Discussion
In the original 1987 report, azinomycin B was found to
have no biological effect against yeast [17]. We have ex-
amined azinomycin B against cultures of Saccharomy-
ces cerevisiae and observed cytotoxic activity at moder-
ate concentrations (ED50 = 10 mg/ml). In this report, we
have used yeast as a model organism to establish the
cellular origin of cytotoxicity exhibited by this agent.
Cellular Localization of Azinomycin B
In efforts to substantiate the purported biological role
of azinomycin B as a DNA crosslinking agent, we initially
examined the localization pattern of the agent in yeast
by using fluorescence microscopy. In earlier work, Cole-
man and coworkers reported the following UV/vis
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486spectrum for the azinomycin naphthoate: lmax (MeOH/
H2O, 1:1) 240 (3 34,000), 298 (3 6,300), 338 nm (3 7,400).
They also described fluorescence contact energy trans-
fer experiments in which emission by the naphthoate
was observed at 435 nm [9]. This fluorescence range is
comparable to that exhibited by the fluorescent stain
DAPI, which has excitation and emission wavelengths
of 345 nm and 455 nm, respectively.
At 10003 amplification, yeast treated with azinomycin
B exhibited localized binding and fluorescence (Fig-
ure 2). Saccharomyces cerevisiae cells were treated
with azinomycin B (100 mg/ml and a blast treatment of
4000 mg/ml; Figures 2A and 2B) or the naphthoate core
of azinomycin (DNA nonbinder; 500 mg/ml; Figure 2D),
and they were compared to ethanol-fixed yeast cells
(Figure 2C) and fixed cells stained with the DNA interca-
lator propidium iodide (1 ng/ml; Figure 2E). After incuba-
tion for 4 hr, cells were centrifuged and resuspended
in phosphate-buffered saline. Cells were viewed with a
Zeiss fluorescence microscope, and the images were
captured digitally, under constant image capture condi-
tions.
The pattern of fluorescence exhibited by azinomycin
B paralleled that exhibited by propidium iodide, in which
staining of the nuclear region of the cell was observed
(i.e., the area of the cell that surrounds the central
body or vacuole storage organelle of yeast). In contrast,
control cells treated with ethanol showed diffuse back-
ground fluorescence (Figure 2C), as did yeast cells
treated with the azinomycin naphthoate (a DNA non-
binder; Figure 2D). These results provide evidence that
azinomycin B is concentrated in the cell nucleus, which
would be expected for an agent that interacts covalently
with duplex DNA.
Figure 1. Structures of Azinomycins A and BDNA-Damaging Effect of Azinomycin B
The nuclear effects of the agent were further corrobo-
rated by the DNA damage that resulted with azinomycin
exposure. Genomic DNA isolated from yeast treated
with the natural product demonstrated increased shear-
ing of the DNA as compared to yeast cells incubated
with ethanol alone (Figure 3). Moreover, a dose-depen-
dent response was observed.
Transcriptional Response and Cell Cycle Analysis
The effect of azinomycin B on the yeast transcriptome
was examined by using Affymetrix oligonucleotide mi-
croarrays (Yeast S98 Array). Data were obtained at two
concentrations of agent (Table 1). Drug treatment was
carried out in duplicate at the ED50 concentration (10
mg/ml) and a 10-fold higher concentration (100 mg/ml)
for 6 hr. The data in Table 1 are remarkably consistent
with the proposed mode of action of azinomycin B as
a DNA-damaging agent. Differential mRNA gene expres-
sion (R2-fold) was observed in 47 transcripts out of
w6200 genes that comprise the yeast genome. Approx-
imately 57% of those differentially expressed transcripts
Figure 3. Effect of Azinomycin B on Genomic DNA, 1% Agarose
Gel Visualized with SYBR Green
Yeast cells were cultured to 1.0 OD and treated with ethanol vehicle
or azinomycin B for 12 hr. Lane 1, DNA ladder; lane 2, EtOH control;
lane 3, azinomycin B (10 ml); lane 4, azinomycin B (100 ml).Figure 2. Cellular Localization of Azino-
mycin B
(A) Yeast treated with azinomycin B for 6 hr;
100 mg/ml.
(B) Yeast treated with azinomycin B for
6 hr; w4000 mg/ml.
(C) Yeast treated with ethanol for 6 hr;
control.
(D) Yeast treated with naphthoate (non-DNA
binder); w500 mg/ml.
(E) Yeast fixed with ethanol and stained with
propidium iodide.
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487Table 1. Effect of Azinomycin B on Gene Expression in Yeast
Fold Change
Upregulated Probe Set Gene Description 10 mg/ml 100 mg/ml
Nuclear/DNA Damage
4045_s_at YIL066C ribonucleotide reductase large subunit 2.5 —
5643_at YER070W ribonucleotide reductase — 3
5626_at YER095W RecA homolog, RAD 51, involved in recombinational repair — 3
5970_at YDR501W, PLM2 plasmid maintenance 2.6 9
3262_at YGLCTAU3 Ty4 LTR — 14.6
3200_I_at YHLWDELTA2 Ty1 LTR — 23.7
10222_at YLR103 chromosomal DNA replication protein — 6.3
7352_at YBL009W, strong similarity to DNA damage-responsive Alk1 p — 4.1
3058_s_at YHR015W DNA helicase and DNA-dependent ATPase involved in DNA repair — 3.2
8639_at YOL104C in meiotic chromosome segragation, might stabililize homologous
DNA interactions at telomeres
— 4.3
6293_at YDR191W, homolog of SIR2 — 9.08
Cell Signaling/Cell Cycle
9293_at YML058w-a identified by SAGE, Hug-1, involved in cell cycle checkpoint and arrest 16 73
5108_at YGL089C a mating factor 2.1 5.7
8028_at YPL267W weak similarity to C. elegans transcription factor unc-86 — 4.18
6021_f_at YDR461W a-factor mating pheromone precursor — 10.3
6585_at YDL101C protein kinase — 3.7
10164_at YLR183C similarity to YDR501w, transcription factor induced in G1,
bind to promoter in the cell cycle
— 21.6
Ribosomal Proteins
7190_I_at YBR189W ribosomal protein S9B (S13)(rp21)(YS11) — 8.6
7191_f_at YBR189W ribosomal protein S9B (S13)(rp21)(YS11) — 7.1
6069_I_at YDR418W ribosomal protein L12B (L15B)(YL23) — 3.3
5076_f_at YGL076C ribosomal protein L7A (L6A)(rp11)(YL8) — 4.1
11237 _at YJL189W ribosomal protein L39 (L46)(YL40) — 4.7
11235_at YJL191W ribosomal protein S14B (rp59B) — 6.4
10068_I_at YLR264W ribosomal protein S28B (S33B)(YS27) — 8.3
9497_I_at YMR143W ribosomal protein S16A (rp61R) — 4.5
9006_s_at YNL162W ribosomal protein L42A (YL27)(141A) — 4.5
Unclassified Genes
7792_at YPL051W strong similarity to ADP-ribosylation factors — 3.8
7697 _I_at YPR077C questionable ORF, gene function unknown — 4.3
9075_at YNL227C similarity to dnaJ-like proteins, possible cochaperone — 6.6
4854_at YGR153W hypothetical protein, uncharacterized — 4.4
49R1 at YGR035C hypothetical protein, potential Cdc28p substrate — 6.1
5365_at YFR023W poly(A) binding protein, related to PES4 protein homolog — 3.5
Fold Change
Downregulated Probe Set Gene Description 10 mg/ml 100 mg/ml
Nuclear/DNA Damage
3310_s_at YERWDELTA18 Ty1 LTR — 25.8
4692_f_at TY element transposition — 25.9
7513_f_at TY element transposition — 24.7
8752_f_at TY element transposition — 25.7
11323_at YAL001C transcription factor tau (TFIIIC) subunit 138 23.2 —
3248_s_at YGR109W-B, DNA and RNA binding, RNA-dependent DNA replication,
transferase activity
23 —
3712_s_at YNRCTY1-3 full-length Ty1, transposon 23.9 —
3913_s_at YARCTY1-1 full-length Ty1, transposon 23.6 —
Cell Signaling/Cell Cycle
2350 s at YDR457W or Tom1, ubiquitin ligase, required for G2/M transition 23.2 —
Transport
4842_at YGR142W involved in intracellular protein transport 23.6 —
2642_s_at YOR153w or PDR5, transporter, exhibits nucleoside triphosphatase activity 23.9 —
2643_s_at YOR153w or PDR5, transporter, exhibits nucleoside triphosphatase activity 24 —
Mitochondrial
10934_at YJR095W protein related to mitochondrial carriers — 27.8
5679_at YER024W similarity to carnitine O-acetyltransferase Yat1p — 24
4005_at Cytochrome C oxidase subunit I — 27.2
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488were nuclear related, including genes involved in DNA
repair, DNA maintenance, and cell cycle control as well
as genes for transposons. The remaining genes included
ribosomal proteins, mitochondrial genes, transporter
proteins, and a few unclassified genes.
Among the nuclear effects, Ty elements were largely
affected by azinomycin treatment. While the expression
of YGLCtau3 Ty4 LTR and YHLWdelta2 Ty1 LTR was
upregulated by a remarkable 15- and 24-fold, respec-
tively, most transposition elements (a total of 7) were re-
pressed 3- to 6-fold. LTR retrotransposons have been
extensively studied in Saccharomyces cerevisiae, and
five distinct families, designated Ty1, Ty2, Ty3, Ty4,
and Ty5, have been identified in this organism [19]. The
Ty elements transpose through an RNA intermediate by
reverse transcription [20]. While differential expression
of these genes could reflect a general cellular stress re-
sponse, differential expression was not observed with
other DNA-damaging agents, including the DNA-alkylat-
ing agent methyl methanesulfonate and the DNA-cleaving
agent calicheamicin g1I [21]. Moreover, recent studies
have shown that when DNA replication is compromised
in yeast, Ty elements constitute a preferred site for
double-strand DNA breaks, analogous to fragile sites
observed in mammalian chromosomes [22].
Additionally, classification and correlation of the ma-
jority of the gene changes revealed activation of genes
in the MEC1 checkpoint or sensory pathway, which is
involved in DNA double-strand break repair (Figure 4).
DUN1, a serine-threonine kinase required for DNA dam-
age-induced transcription, plays a pivotal role in the
MEC1 pathway and was enhanced in its expression by
4-fold. The cell cycle checkpoint protein induces G2/M
arrest after DNA damage and controls postreplicative
DNA repair [23]. In this regard, we observed downregu-
lation of TOM1 (YDR457w), a ubiquitin ligase required
for the G2/M transition [24, 25]. The yeast pheromones
a-mating factor and a-mating factor were upregulated
6- and 10-fold, respectively, in expression. Both phero-
mones act by G1 phase synchronization of cell popula-
tions in preparation for mating [26]. The expression of
MF(ALPHA)2 was upregulated 2-fold and 6-fold at 10
mg/ml and 100 mg/ml, respectively, and MFA1 was upre-
gulated 10-fold. Cells respond to these pheromones
during conjugation and cellular fusion, and they interact
to induce cell cycle arrest [27, 28]. Tos4 (or TLR183c),
a transcription factor that binds promoter regions of
genes involved in pheromone response and cell cycle,
was upregulated 22-fold. Expression of TOS4 is induced
in G1 by bound SBF (Swi4-Swi6 cell cycle box binding
factor) [29, 30]. The SBF factors bind the promoters of
genes with roles in G1/S events, including DNA replica-
tion, bud growth, and spindle pole complex formation,
as well as the general activities of mitochondrial func-
tion, transcription, and protein synthesis [31]. DUN1
has also been shown to regulate the expression of
HUG1 or YML058w-a, a protein involved with the DNA
damage checkpoint response, controlling replication ar-
rest; it was upregulated 16-fold and 73-fold at 10 mg/ml
and 100 mg/ml, respectively [32].
Similarly, DUN1 has been shown to regulate double-
strand break repair, resulting in activation of DNA dam-
age repair genes, which is a major mechanism for provi-
ding genomic stability. Critical DNA repair genes wereupregulated in response to azinomycin B treatment. The
DNA strand exchange protein RAD51, which is involved
in recombinational repair of double-strand breaks [33],
was enhanced in expression by 3-fold. Deletion of this
gene has been demonstrated to give rise to the accumu-
lation of double-strand breaks, and the resulting lesions
are both radiation sensitive and defective in gene
conversions [34]. PLM2, a transcription factor involved
with plasmid stability and maintenance, was upregu-
lated in its expression, exhibiting a dose-dependent re-
sponse [29]: mRNA expression of this gene product
was enhanced almost 3-fold and 9-fold at 10 mg/ml and
100 mg/ml, respectively. HST4 (YDR191W), a member
of the SIR2 family of protein deacetylases [29], was in-
creased in expression by 9-fold. This protein has a vari-
ety of biological roles, including double-strand break
repair, silencing of telomeres, cell cycle progression, ra-
diation resistance, genomic stability, and involvement in
short-chain fatty acid metabolism [35]. Likewise, expres-
sion of SRS2 (YJL092W), a DNA helicase and DNA-de-
pendent ATPase involved in DNA/double-strand break
repair by nonhomologous end-joining [36, 37], was upre-
gulated more than 3-fold, and YBL009W, a protein with
strong similarity to the DNA damage response element,
was enhanced 4-fold.
Genes involved in DNA synthesis and replication were
also affected by azinomycin exposure, consistent with
the DNA damage and crosslinking effects demonstrated
for the agent in vitro. For example, the expression of the
chromosomal DNA replication protein YLR103C [38, 39]
was upregulated more than 6-fold. The expression of
ribonucleotide reductase subunits RNR1 and RNR3
was upregulated 3-fold. These subunits comprise com-
ponents of the ribonucleotide-diphosphate reductase
(RNR) large subunit, which catalyzes the rate-limiting
step in dNTP and DNA synthesis, and which is tightly
regulated by DNA replication and DNA damage check-
point pathways [40]. DUN1 null mutants, for example,
have been shown to not only be defective in DNA
Figure 4. Correlation of Gene Changes from a Transcriptional
Array Profile Showing General Activation of the MEC1 Checkpoint
Pathway
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Azinomycin B Treatment
(A) Wild-type yeast cells stained with Sytox
Green.
(B) Cell cycle analysis of wild-type yeast
cells.
(C) Cell cycle profile of yeast cultured for 6 hr,
control (pink); 10 mg/ml azinomycin (blue);
and 100 mg/ml azinomycin (green).
(D) Cell cycle profile of yeast cultured for 12 hr,
control (pink); 10 mg/ml azinomycin (blue);
and 100 mg/ml azinomycin (green).damage repair, but also to be defective in DNA damage-
responsive induction of RNR genes (Saccharomyces
Genome Database [SGD]).
Cell Cycle Effects
When the gene-profiling results are integrated, the tran-
scriptional effects of azinomycin B treatment in yeast
suggest a G1/S phase shift. In order to corroborate these
findings, we examined the effects of azinomycin B on the
yeast cell cycle. Yeast cells were treated with azino-
mycin B at concentrations of 10 mg/ml and 100 mg/ml
for 6 hr and 12 hr, respectively, and were examined by
flow cytometry (Figure 5) [41]. Figure 5A shows wild-
type yeast cells stained with Sytox Green. Figure 5B
depicts the cell cycle analysis of these cells. Figures
4D and 5C show the cell cycle profile of yeast cells at
6 hr and 12 hr, with and without azinomycin B treatment.
When compared to the wild-type cells, azinomycin
B-treated cells exhibited a predominant S phase shift.
A decrease in the G2/M population was apparent at
12 hr at both concentrations of agent.
Confirmation of Selected Gene Changes by RT-PCR
Validation of the transcriptional effects induced by
azinomycin B treatment was demonstrated by semi-
quantitative reverse transcriptase (RT)-PCR of an arbi-
trary subset of the gene changes, including HUG1,
RAD51, TOM1, and PLM2. The procedure, while less
sensitive and quantitative than real-time PCR, is capable
of confirming a transcriptional response that is marked
by the presence or absence of a transcriptional effect.
Normalization of the RNA/cDNA was based on glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) that
was unaffected by drug exposure. Total RNA was ex-
tracted from control cells and cells treated with azino-mycin B (10 mg/ml and 100 mg/ml). First-strand cDNA
synthesis of the DNA was performed, followed by PCR
analysis. The exponential phase of each PCR product
was estimated by varying the number of PCR cycles
for each template or gene of interest [42]. PCR products
were stained with SYBR Green, and fluorescence was
measured with a microplate reader (Figure 6).
Significance
Azinomycins A and B are natural products that pos-
sess promising antitumor activity. Central to the bio-
logical action of these molecules is the presence of
two electrophilic carbons present within the epoxide
moiety and the structurally and functionally unique
aziridino[1,2-a]pyrrolidine core substructure. Evalua-
tion of the azinomycins in vitro has demonstrated that
the molecules bind to DNA within the major groove
and form covalent interstrand crosslinks. The exqui-
site ability of these natural products to functionalize
Figure 6. Semiquantitative Reverse Transcriptase-PCR Analysis of
the Genes HUG1, RAD51, PLM2, and TOM1
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490and append to DNA notwithstanding, the cellular tar-
get of these molecules in vivo has yet to be estab-
lished. In efforts to address this issue, we have exam-
ined the cellular localization pattern of azinomycin B in
Saccharomyces cerevisiae, which paralleled that of
the DNA intercalator propidium iodide.
Additionally, genomic DNA isolated from drug-
treated cells showed significant shearing of the DNA,
and experiments with oligonucleotide microarrays re-
vealed transcriptional effects that were closely associ-
ated with DNA damage and repair. Genes involved in
DNA synthesis and the cell cycle were altered in their
expression, reflecting an S phase shift. This effect was
further substantiated in flow cytometry experiments.
Some genes differentially expressed in response to
azinomycin B treatment were also induced by caliche-
amicin g1I or methyl methanesulfonate exposure, al-
though a significant number of the genes that were
effected by azinomycin B were not common to these
other agents. Transcriptional profiling could prove to
be a definitive tool in the study of the mechanism of
action of DNA-damaging agents.
These results provide the first demonstration of the
in vivo actions of azinomycin B.While the experiments
presented here are consistent with the proposed role
of the drug as a DNA crosslinking agent, definitive
proof for this mechanism must come from experi-
ments that can conclusively demonstrate drugDNA
adduct formation.
Experimental Procedures
Instrumentation and General Methods
Yeast cell cycle experiments were performed with a Becton-Dickin-
son FACS Calibur flow cytometer. RT-PCR reactions were carried
out with an MJ Research PT600 PCR machine, and fluorescence
measurements were made with a Biotek FL800 fluorescence micro-
plate reader. Cellular localization studies were conducted with a
Zeiss microscope, and the Affymetrix platform was used in all Gen-
eChip experiments. Unless otherwise specified, biochemical re-
agents were obtained from Sigma Biochemicals (St. Louis, MO).
Organisms
The yeast S. cerevisiaewild-type strain (#404; BY4741; MATa his3D1
leu2D0 met15D0 ura3D0) was obtained from Dr. Michael Kladde at
the Department of Biochemistry, Texas A&M University. Streptomy-
ces sahachiroi (NRRL 2485) was obtained from the American Type
Culture Collection (ATCC; Manassas, VA).
Culture Conditions
Saccharomyces cerevisiae was maintained on YPD plates and sub-
sequently cultured at 30ºC and 250 rpm in YPD medium [43]. Strep-
tomyces sahachiroi was initially cultured on GYM plates until sporu-
lation, typically 5–7 days at 28ºC. GYM agar plates contained the
following components per liter: glucose monohydrate, 4 g; yeast ex-
tract, 4 g; malt extract, 10 g; CaCO3, 2 g; agar, 12 g; and tap water;
adjusted to pH 6.8 with 1 M NaOH prior to sterilization [44]. A starting
culture of Streptomyces sahachiroi in PS5 medium (100 ml) was pre-
pared by inoculation of a loop of spores from the GYM plates. PS5
medium was prepared from 5 g/l Pharmamedia (yellow cotton
seed flour, Traders Protein; Memphis, TN) and 5 g/l soluble starch,
adjusted to pH 7.0. After 24 hr of growth at 30ºC and 250 rpm, 25 ml
of the starting culture was used to inoculate 500 ml PS5 in 2 liter
baffled Erlenmeyer flasks. The cultures were grown for 64 hr at 30ºC
and 250 rpm [44].
Azinomycin B Isolation
The natural product was isolated with slight modification of literature
protocols [4, 45]. After fermentation, culture broths of Streptomycessahachiroi were harvested by centrifugation (8000 rpm). The super-
natant was extracted once with an equal volume of chloroform. The
chloroform extract was concentrated to 5 ml and diluted with hex-
ane (30 ml). The resulting suspension was centrifuged (3000 rpm),
giving a white azinomycin-containing precipitate that was further
purified by washing with ether (10 ml), followed by dissolution in
chloroform (50 ml). Hexane was added gradually, and with the initial
addition of hexane, a precipitate was generated and discarded. Fur-
ther addition of hexane resulted in the precipitation of azinomycin B
as a white, amorphous solid. The azinomycin was collected by cen-
trifugation and stored under anhydrous diethyl ether at 280ºC.
Nuclear Localization Experiments
Yeast cells were grown at 30ºC in liquid culture to an OD600 of 1.0.
Isolates (1 ml) were centrifuged, and the cell pellets were resus-
pended in 1 ml sterile Dulbecco’s phosphate-buffered saline. The
cells were centrifuged and treated with (1) 100 mg/ml and 4000 mg/
ml azinomycin (live cells), (2) 500 mg/ml naphthoate [5, 46], and (3)
1 mg/ml propidium iodide. Propidium iodide-stained cells were fixed
by the addition of 70% ethanol (final volume, 30 min of incubation at
room temperature) prior to resuspension in Dulbecco’s phosphate-
buffered saline and treatment with propidium iodide. After 4 hr of in-
cubation at room temperature, the cells were centrifuged, the super-
natant was removed, and the cells were resuspended in Dulbecco’s
phosphate-buffered saline. The cells were viewed on slides with a
Zeiss fluorescence microscope, and the images were captured dig-
itally at 10003magnification. The conditions for image capture were
held constant.
Genomic Analysis
Saccharomyces cerevisiae was cultured in 10 ml aliquots at 30ºC to
an OD600 of 1.0 and was subsequently treated with either 100 ml azi-
nomycin B or ethanol (to give final concentrations of 10 mg/ml and
100 mg/ml, respectively). The cells were cultured for an additional
12 hr with shaking and were centrifuged, and the genomic DNA
was isolated as follows. The cells were resuspended in 500 ml solu-
tion consisting of 1 M sorbitol and 0.2 M EDTA (pH 7.5), at which
point 5 ml zymolyase (0.5 mg/ml) was added, and the suspension
was incubated at 37ºC for 60 min. The cells were centrifuged, resus-
pended in 500 ml 50 mM Tris (pH 7.4), 20 mM EDTA, and 25 ml 20%
SDS was added. After incubation of the mixture at 50ºC for 30 min,
5 ml proteinase K (10 mg/ml) and 200 ml 5 M potassium acetate
were added to the solution. The reaction was placed on ice for 60
min, and the cellular debris was removed by centrifugation. The su-
pernatant was transferred to a new tube, and one volume of isopro-
panol was added. The mixture was allowed to stand at room temper-
ature for 5 min. The DNA was isolated by centrifugation (5 min) and
was dissolved in 100 ml TE buffer containing 1 ml RNase. The suspen-
sion was incubated at 37ºC for 30 min, at which time the DNA was
precipitated by the addition of 400 ml 5 M NH4OAc and 200 ml isopro-
panol, centrifuged, washed with 1 ml 80% EtOH, dried, and dis-
solved in 100 ml TE buffer. The DNA, 5 ml of each sample, was ana-
lyzed by agarose gel electrophoresis and stained with SYBR
Green by following the manufacturer’s protocol (Molecular Probes,
Invitrogen; Carlsbad, CA).
Yeast Sample Preparation and GeneChip Evaluation
Yeast cells were cultured overnight in YPD broth [43] to an OD600 of
1.0. Total RNA was extracted with an SDS/hot phenol extraction
method. Yeast cell samples were centrifuged, and the supernatant
was decanted. Each cell sample was washed with 30 ml deionized
distilled water and subsequently centrifuged (repeated three times).
Yeast pellets were frozen in liquid nitrogen and lysed by using the
following protocol. Each cell pellet was treated with 103 high-salt
solution (3 M NaCl, 200 mM Tris [pH 8.0], 100 mM EDTA) and deion-
ized distilled water to a final volume of 700 ml. Each sample was
brought to 1% SDS by the addition of 10% SDS (70 ml), at which
time hot phenol (65ºC, 600 ml) was added. Samples were vortexed,
incubated at 65ºC for 4 min, and chilled on ice for 2–4 min. Samples
were microcentrifuged for 2 min, and the supernatant was trans-
ferred to new tubes. The phenol extraction procedure was repeated,
and it was followed by extraction with a 25:24:1 phenol:chloroform:
isoamyl alcohol. After centrifugation, the supernatant of each sam-
ple was transferred to new tubes. The RNA was precipitated by
Cellular Effects Induced by Azinomycin B
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were mixed by vortexing, stored at 20ºC for 1 hr, and pelleted by
centrifugation. The supernatant was decanted, and the pellet from
each sample was washed twice with 70% ethanol. Residual ethanol
was removed, and the cell pellet was resuspended in 100 ml water.
The resulting total RNA was then treated with DNase: total RNA
(30 ml) was incubated at room temperature with 5 ml of first-strand
buffer (GIBCO-BRL cDNA Superscript Choice Kit) and 1 ml DNase I
(RNase-free, Ambion). Samples were heat inactivated at 75ºC for
15 min and purified with an RNeasy kit (Qiagen). Samples (15 mg of
total RNA per sample) were provided to the Texas A&M GeneChip
facility, where they were amplified, biotinylated, and hybridized to
GeneChips according to the protocol detailed by Affymetrix (Santa
Clara, CA). Microarray data are available through the NCBI Geo Da-
tabase (accession number: GSE4311).
GeneChip Evaluation by RT-PCR
RT-PCR analysis of a subset of the genes, including HUG1, RAD51,
TOM1, and PLM2, was carried out as follows. Total RNA (10 mg) was
extracted and transcribed into single-stranded cDNA by using the
Superscript Choice system (GIBCO-BRL). The cDNA was purified
with a Qiagen nucleotide removal kit. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was employed as an endogenous amplifi-
cation standard (i.e., used to normalize the amount of RNA in control
and treatment samples). PCR conditions were optimized so that am-
plification of both GAPDH and the cDNA of interest was in the expo-
nential phase. PCR cycles consisted of step 1: 5 min denaturation at
95ºC; step 2: 1 min of denaturation at 95ºC; step 3: 1 min of primer
annealing at 55ºC; step 4: 1 min of extension at 72ºC. Steps 2–4
were repeated for the requisite number of cycles.
Primers
The following primers were used:
HUG1 (YML058W-A): forward: 50-ATGACCATGGACCAAGGCCT
TAACC-30, reverse: 50-TTAGTTGGAAGTATTCTTACCAATG-30
RAD51 (YER095W): forward: 50-CGGATGTGAAAAAACTAAGG
GAGAG-30, reverse: 50-TCTTAACTGATGATCGGCGTTATAG-30
TOM1 (YDR457W): forward: 50-AACAGCTCGGTTCCATGAATTT
GAT-30, reverse: 50-TAATTACGGAACGTGCTAGCATTCC-30
PLM2 (YDR501W): forward: 50-TTGGCTAAAGGTGAAACTGTT
ACTT-30, reverse: 50-GCGAAAGATTCTTCTTCATTAATGC-30
GAPDH (YJR009C): forward: 50-ACATTGACATCGCCATTGACT
CCAC-30, reverse: 50-TTTCATCGTAGGTGGTTTCCTTGTT-30
After PCR, each reaction was visualized by agarose gel electro-
phoresis (15 ml per lane) and stained with ethidium bromide. The re-
sulting PCR products were sliced out of the gel and dialyzed against
TAE buffer [47]. The dialyzed gel pieces were stained with SYBR
Green (Molecular Probes, Invitrogen) and placed in a 96-well plate,
and fluorescence was measured with a Biotek FL800 microplate
reader (filters: 485/30 for excitation and 528/20 for emission).
Cell Cycle Analysis by Flow Cytometry
Yeast cells were grown at 30ºC in liquid culture to an OD600 of 1.0 and
were exposed to azinomycin B (10 and 100 mg/ml, in triplicate) for 6
and 12 hr. The yeast population was asynchronous. Cells were
centrifuged, the medium was removed, and the cells were washed
with 10 mM Tris (pH 7.5). The cells were fixed by treatment with
70% ethanol for 1 hr at room temperature. Cells were centrifuged,
the supernatant was discarded, and the pellet was incubated with
0.5 ml 50 mM Tris (pH 7.5) supplemented with 2 mg/ml RNase A at
37ºC for 2–12 hr. After incubation, cells were centrifuged, and the su-
pernatant discarded. The cells were resuspended in 0.2 ml protein-
ase solution (5 mg/ml pepsin, 4.5 ml/ml concentrated HCl in H2O) for
15–20 min at 37ºC. The cells were centrifuged, the supernatant was
discarded, and the cells were resuspended in 0.5 ml Tris (pH 7.5) and
13 Sytox Green (100 nM; Molecular Probes, Invitrogen), followed
directly by the analysis step [48].
Supplemental Data
Supplemental Data including quantitative distribution analyses of
yeast cell cycle populations are available at http://www.chembiol.
com/cgi/content/full/13/5/485/DC1/.Acknowledgments
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